Chemistry42’s Post

Our latest research, driven by PandaOmics, identified MYT1 as a promising therapeutic target for breast and gynecological cancers, with our lead compound 21, demonstrating remarkable selectivity and promising in vivo antitumor efficacy. Through structure-based drug design, we optimized potency and physical properties, offering a potential breakthrough in innovative treatment options for these deadly diseases. To read the paper: https://lnkd.in/gb-J463c #CancerResearch #DrugDiscovery #PrecisionMedicine

Bemarituzumab is a humanized monoclonal antibody that is selective for FGFR2b. Learn how the addition of #bemarituzumab to mFOLFOX6 can result in longer PFS and OS rates compared with mFOLFOX6 alone in patients with FGFR2b-positive advanced #gastriccancer:

Please join this week's Educational Webinar: "Investigational Treatment for KRAS-Mutated Cholangiocarcinoma-An Unmet Need," with Carol Addy from GENFIT and Mark Yarchoan from Johns Hopkins Kimmel Cancer Center. There are currently no approved therapies for patients with KRAS-mutated cholangiocarcinoma. In this webinar, you will learn about an ongoing Phase 1b/2a study that is aimed to evaluate the combination of GNS561, an autophagy inhibitor, and trametinib, a MEK-inhibitor, as a potential novel treatment for patients with unresectable or metastatic KRAS-mutated cholangiocarcinoma. Visit https://lnkd.in/eSSuNxiR to register. #Cholangiocarcinoma #CCA #RareDisease #LiverDisease #Cancer #MedicalEducation #GENFIT #GNFT

Exposure to UV radiation fuels the malignant melanoma treatment market, with UVA and UVB damaging DNA, leading to mutations. Johnson & Johnson, and Pfizer are key players. Focus on innovative drug development, exemplified by Bristol Myers Squibb's Opdualag, drives market growth. Collaborations like Immatics partnering with Bristol Myers Squibb aim for advanced cancer therapies. Market segments include treatment type, disease, and end-users. North America leads, with Asia-Pacific forecasted for rapid growth. Expected to reach $7.21 billion in 2024, growing at a 12.0% CAGR, and $10.85 billion by 2028. Targeted therapies, patient awareness, and AI integration are key drivers, while early detection tech and precision medicine are emerging trends. Read more https://lnkd.in/gbfqyvf5 #MelanomaTreatment #UVRadiation #Innovation #Collaboration #MarketGrowth #tbrc #thebusinessresearchcompany #marketresearch #marketintelligence

We've successfully completed the full recruitment of our Phase 2 trial of SNT-5055, a pan-LOX inhibitor combined with ruxolitinib, aimed at treating the bone marrow cancer myelofibrosis. The trial, which began in December 2023 across 19 sites in the USA, Australia, South Korea, and Taiwan, has now dosed its 15th patient and exceeded the one-month treatment threshold for 12 patients required for FDA safety evaluation. No drug-related dropouts or serious adverse reactions have been observed. Interim results are expected in December 2024, coinciding with the ASH Annual Meeting, potentially paving the way for pivotal FDA discussions in early 2025. The full 12-month data set will be available in Q3 2025. CEO Gary Phillips said: “I’d like to thank the haematology clinics, investigators and the Syntara clinical team for achieving this significant milestone in such a timely fashion. We now look forward to presenting our interim data later in the year and building a solid foundation for the next stage of discussions with the FDA and potential strategic partners. Read the full ASX Announcement here: https://lnkd.in/g7d9fsqP #SNT #Syntara #ClinicalTrials #SNT5055 #Ruxolitinib #Myelofibrosis #BoneMarrowCancer #CancerResearch #FDAEvaluation #Phase2Trial #OncologyResearch #DrugDevelopment

As the countdown to World Theranostics Day continues, we're sharing some fun facts. We narrowed our list to 4, but there are so many more. 1️⃣ Use of Theranostics began 80 years ago with Dr. Saul Hertz. 2️⃣ The debate over using Theranostics or Theragnostics rages on. Most leave out the “g”. 3️⃣ The concept of Theranostics is used to find and detect more than just cancer (Alzheimer’s Disease, Hyperthyroidism, Cardiac Disease, Parkinson’s). 4️⃣ Right now, 7 radiopharmaceutical treatments are FDA approved, but at least 80 radiopharmaceutical drugs are in development. Now want to hear from you! Add your fun Theranostics facts to the comments and let’s keep the conversation going. #Theranostics #WorldTheranosticsDay

A phase 3 study (AK104-308) of #cadonilimab (PD-1/CTLA-4) in combination with lenvatinib and transarterial chemoembolization (TACE) for unresectable, nonmetastatic #hepatocellularcarcinoma (#HCC) has enrolled its first patient. Based on promising phase 2 clinical results published at #ASCOGI 2024，we have progressed to phase 3 trials for advanced uHCC. Simultaneously, a phase 3 trial evaluating cadonilimab as adjuvant therapy for hepatocellular carcinoma after curative resection is also underway. #cadonilimab #HCC #immunotherapy

💊 Results from the phase 2 DESTINY-Gastric03 trial has revealed encouraging results for the combination of trastuzumab deruxtecan, #pembrolizumab, and #chemotherapy in treating patients with HER2-positive advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma:

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions https://bit.ly/3SAfXNE #PancreaticCancer #OvarianCancer #BreastCancer #ColorectalCancer #LongCOVID #MECFS

Today at #ASCO2024 we are presenting a Trials in Progress poster detailing our ongoing clinical studies of IMSA101, a novel small molecule STING agonist, and the first STING agonist to be advanced to randomized Phase 2 clinical studies. IMSA101’s defense-sensing mechanism enables first-in-class potential and numerous combination opportunities. In these studies, supported by $16 million from CPRIT, IMSA101 is being evaluated by randomized combination with both hyper fractionated radiation and immune checkpoint inhibitors. This randomized study is being conducted in two different patient populations, oligoprogressive disease (OPD) and oligometastatic disease (OMD) solid tumor malignancies. https://lnkd.in/gwCnnhxU